Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/3320
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Valerie, F. Boltz | - |
dc.contributor.author | Yu Zheng | - |
dc.contributor.author | Lockman, Shahin | - |
dc.contributor.author | Feiyu, Hong | - |
dc.contributor.author | Halvas, Elias K | - |
dc.contributor.author | McIntyre, James | - |
dc.contributor.author | Ong'or, Willis Owino | - |
dc.date.accessioned | 2020-08-05T07:32:09Z | - |
dc.date.available | 2020-08-05T07:32:09Z | - |
dc.date.issued | 2011-04 | - |
dc.identifier.uri | https://doi.org/10.1073/pnas.1105688108 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/3320 | - |
dc.description.abstract | In the OCTANE/A5208 study of initial antiretroviral therapy (ART) in women exposed to single-dose nevirapine (sdNVP) ≥6 mo earlier, the primary endpoint (virological failure or death) was significantly more frequent in the NVP-containing treatment arm than in the lopinavir/ritonavir-containing treatment arm. Detection of NVP resistance in plasma virus at study entry by standard population genotype was strongly associated with the primary endpoint in the NVP arm, but two-thirds of endpoints occurred in women without NVP resistance. We hypothesized that low-frequency NVP-resistant mutants, missed by population genotype, explained excess failure in the NVP treatment arm. Plasma samples from 232 participants were analyzed by allele-specific PCR at study entry to quantify NVP-resistant mutants down to 0.1% for 103N and 190A and to 0.3% for 181C. Of 201 women without NVP resistance by population genotype, 70 (35%) had NVP-resistant mutants detected by allele-specific PCR. Among these 70 women, primary endpoints occurred in 12 (32%) of 38 women in the NVP arm vs. 3 (9%) of 32 in the lopinavir/ritonavir-containing arm (hazard ratio = 3.84). The occurrence of a primary endpoint in the NVP arm was significantly associated with the presence of K103N or Y181C NVP-resistant mutations at frequencies >1%. The risk for a study endpoint associated with NVP-resistant mutant levels did not decrease with time. Therefore, among women with prior exposure to sdNVP, low-frequency NVP-resistant mutants were associated with increased risk for failure of NVP-containing ART. The implications for choosing initial ART for sdNVP-exposed women are discussed. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Ampath | en_US |
dc.subject | mother-to-child transmission | en_US |
dc.subject | single-dose nevirapine | en_US |
dc.title | Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.